ERBB2 and breast carcinoma: Moreover, targeting HER2 and CD3 in mass forming such as breast cancer using tri-specific cell engager molecules has been developed by adding further CD28 into another binding arm for co-stimulating T-cell response against HER2-positive breast cancer.